help button home button Endocrine Society Endocrinology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Bui, T.
Right arrow Articles by Straus, D. S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Bui, T.
Right arrow Articles by Straus, D. S.
Endocrinology Vol. 138, No. 3 985-993
Copyright © 1997 by The Endocrine Society

Articles

Prostaglandin A2 Specifically Represses Insulin-Like Growth Factor-I Gene Expression in C6 Rat Glioma Cells1

Tim Bui, Chiaoyun Kuo, Peter Rotwein2 and Daniel S. Straus

Biomedical Sciences Division and Biology Department, University of California (T.B., C.K., D.S.S.), Riverside, California 92521-0121; and Departments of Internal Medicine, and Biochemistry and Molecular Biophysics, Washington University School of Medicine (P.R.), St. Louis, Missouri 63110

Address all correspondence and requests for reprints to: Daniel S. Straus, Biomedical Sciences Division, University of California, Riverside, California 92521-0121. E-mail: daniel.straus{at}ucr.edu


   Abstract
Top
 Abstract
Introduction
 Materials and Methods
 Results
 Discussion
 References
 
The cyclopentenone PGs (PGA and PGJ series) inhibit tumor cell proliferation in vitro and tumorigenesis in vivo via mechanisms that are at present poorly understood. The C6 rat glioma cell line synthesizes and secretes insulin-like growth factor-I (IGF-I), which is believed to act as an autocrine factor for these cells. PGA2 inhibits the proliferation of the C6 cells and causes an increase in the fraction of cells in the G1 phase of the cell cycle. The inhibition of cell proliferation by PGA2 is accompanied by a decrease in the abundance of IGF-I messenger RNA (mRNA). This regulation of IGF-I gene expression is specific, as the abundance of hypoxanthine-guanine phosphoribosyl transferase (HPRT) and ubiquitin mRNA is not significantly affected by PGA2. The repression of IGF-I gene expression is observed at PGA2 concentrations as low as 10 µM and is evident within 4 h after treatment of the C6 cells with PGA2. In addition to specifically regulating the expression of the IGF-I gene, PGA2 also decreases the abundance of cyclin D1 mRNA and increases the abundance of Waf1 mRNA. The inhibition of cell proliferation by PGA2 is partially reversed by coaddition of IGF-I, indicating partial dominance of IGF-I action over PGA2 action. To investigate the molecular basis for the regulation of IGF-I gene expression by PGA2, we developed a sensitive RT-PCR assay for IGF-I nuclear transcripts. A similar assay was developed for quantifying HPRT transcripts, which were used as a control. Treatment of the C6 cells with 20 µM PGA2 resulted in approximately a 6-fold decrease in IGF-I mRNA and IGF-I nuclear transcripts. In contrast, HPRT mRNA and nuclear transcript levels were not significantly affected by PGA2. These results indicate that the decrease in IGF-I mRNA abundance that occurs in response to PGA2 is caused largely by a decrease in IGF-I nuclear transcript levels. To identify the cis-acting element that mediates the effect of PGA2 on IGF-I transcription, C6 cells were transiently transfected with IGF-I/luciferase expression constructs in which luciferase transcription is driven by IGF-I P1 promoter fragments extending from -1711 to +328 or from -1114 to +328 relative to the beginning of exon 1. Treatment of cells with PGA2 in these transient transfection assays did not decrease luciferase activity. These results suggest that the cis-acting regulatory element required for the response to PGA2 is located outside the -1711 to +328 promoter interval.


   Introduction
Top
 Abstract
 Introduction
Materials and Methods
 Results
 Discussion
 References
 
THE CYCLOPENTENONE PGs (PGA and PGJ series), which are characterized by an {alpha}, ß-unsaturated ketone in the cyclopentane ring, are potent inhibitors of cell proliferation (1, 2, 3, 4). At growth inhibitory (subtoxic) concentrations, PGA1, PGA2, and PGJ2 arrest cells in the G1 phase of the cell cycle, with little if any effect on cell viability over a 24-h treatment interval (5, 6). PGA and PGJ series PGs also inhibit tumor cell proliferation in vivo, raising the possibility that the cyclopentenone PGs might be useful as chemotherapeutic agents (1, 2, 3, 4).

Very little is known at present about molecular mechanism(s) by which the cyclopentenone PGs inhibit cell proliferation. Treatment of cells with PGA2 results in increased expression of a number of stress-related genes, including HSP70 (7, 8), c-fos (9), and gadd153 (10). The increased expression of these genes appears to involve an increase in gene transcription as well as a posttranscriptional mechanism(s) (7, 8, 9, 10). PGA2 has also been shown recently to increase the expression of the cyclin-dependent kinase inhibitor Waf1 (p21) in MCF-7 breast cancer cells, via a p53-independent mechanism (6, 11). The induction of HSP70 gene transcription involves activation of the heat-shock transcription factor (7, 8). Details concerning the molecular mechanism by which PGA2 increases transcription of the other genes are unknown.

In addition to increasing the expression of certain genes, the cyclopentenone PGs repress the expression of others. For example, PGA2 represses c-myc gene expression in HL60 cells (12), PGA2 and {Delta}12-PGJ2 repress N-myc gene expression in a human neuroblastoma cell line (13), and PGA2 represses cyclin D1 and cyclin-dependent kinase 4 (cdk4) gene expression in MCF-7 breast cancer cells (6). Thus specific negative as well as positive effects on gene expression are observed following treatment of cells with the cyclopentenone PGs. Very little is known at present about the molecular mechanism for repression of gene expression by the cyclopentenone PGs.

The C6 rat glioma cell line synthesizes and secretes insulin-like growth factor-I (IGF-I), which acts as an autocrine growth factor for these cells (14, 15). Transcription of the IGF-I gene in these cells is directed exclusively by the P1 promoter element (14). Interference with IGF-I or IGF-I receptor synthesis by the C6 cells results in suppression of tumorigenicity in vivo (15, 16, 17). The suppression of tumorigenicity that occurs in vivo when IGF-I or IGF-I receptor synthesis is inhibited is characterized by apoptosis of the tumor cells (17, 18). Thus a major role of IGF-I in the autocrine/paracrine stimulation of tumor cell proliferation in vivo may be to protect the cells from undergoing apoptosis. In the present study, we demonstrate that IGF-I messenger RNA (mRNA) abundance is specifically decreased by PGA2 in the C6 cells. Treatment of the C6 cells with PGA2 also leads to a decrease in the abundance of IGF-I nuclear transcripts, suggesting that the effect of PGA2 on IGF-I gene expression is exerted primarily at the transcriptional level. Suppression of autocrine growth factor synthesis represents a previously unknown potential mechanism for the suppression of tumorigenicity by the cyclopentenone PGs.


   Materials and Methods
Top
 Abstract
 Introduction
 Materials and Methods
Results
 Discussion
 References
 
Cell culture experiments
Rat C6 glioma cells were obtained from American Type Culture Collection (Rockville, MD) and cultured in MEM with 10% FBS, penicillin (100 U/ml), and streptomycin (100 µg/ml). PGA2 (dissolved in methyl acetate) was obtained from the Caymen Chemical Co. (Ann Arbor, MI). Before using the PGA2 in experiments, the methyl acetate was evaporated, and the PGA2 was dissolved in ethanol. Human recombinant IGF-I was purchased from R&D Systems (Minneapolis, MN) and dissolved in 10 mM acetic acid at a concentration of 100 µg/ml (14 µM). Growth experiments were carried out using 50 ng/ml (7 nM) IGF-I. For experiments testing the effects of PGA2 on IGF-I gene expression or cell proliferation, cells were plated at a density of 1.5 x 104 cells/cm2 and cultured for 24 h at 37 C. At this time, the cells were in exponential growth phase and were approximately 50–60% confluent. PGA2 or vehicle (ethanol, final concentration 0.067%) was then added to the culture medium. Cells were harvested at various time intervals for counting (using a Coulter ZBI cell counter or hemacytometer), cell cycle analysis, RNA preparation, or luciferase assay. For cell cycle analysis, cells were harvested by trypsinization, resuspended in ice cold PBS, and fixed with methanol (final concentration 67% vol/vol) (19, 20). Cells were then pelleted by centrifugation, stained with propidium iodide (50 µg/ml) in the presence of heat-treated RNase A (1 mg/ml) for 30 min at 23 C, and filtered through 35 µm nylon mesh (19, 20). Cell cycle analysis was performed using a Becton Dickinson FACScan flow cytometer. The percentage of cells in various phases of the cell cycle was analyzed using the CellFIT software program (Becton Dickinson).

DNA clones
DNA clones used as probes for Northern blot analysis were obtained from the following sources: rat IGF-I complementary DNA (cDNA) prigf1-1 (21), G.I. Bell, Howard Hughes Medical Institute, University of Chicago, Chicago, IL; Chinese hamster ubiquitin cDNA clone pH37 (22), A.J. Fornace, NIH, Bethesda, MD; mouse 1.4-kilobase (kb) cyclin D1 cDNA (23), C. Dickson, Imperial Cancer Research Fund Laboratories, London, U.K.; mouse Waf1 (p21) cDNA (24), K. Huppi, NIH, Bethesda, MD; rat 28S ribosomal RNA genomic clone pSPEE6.7 (25), D. Chikaraishi, Tufts University School of Medicine, Boston, MA; mouse hypoxanthine-guanine phosphoribosyl transferase cDNA clone mHPT5, American Type Culture Collection.

For transient transfections, the -1711/+328 and -1114/+328 IGF-I P1 promoter fragments were subcloned from IGF1711b/LUC (26) into the promoterless luciferase vector pGL3-Basic (Promega, Madison, WI). The -1114/+328 promoter fragment was isolated by restriction digestion with SmaI and BamHI and cloned into the SmaI/BglII sites of pGL3-Basic. The -1711/+328 promoter construct was produced by first cloning the -1711/+328 PstI/BamHI restriction fragment into the PstI/BamHI sites of pBluescript KS(-) (Stratagene, Cincinnati, OH). A KpnI/SmaI fragment containing nucleotides -1711 to -1115 of the P1 promoter was then isolated and cloned directly in front of the -1114/+328 promoter fragment in pGL3-Basic. The cytomegalovirus (CMV)-ßgal expression plasmid, in which ß-galactosidase expression is under control of the human cytomegalovirus immediate-early enhancer plus promoter, was obtained from F.M. Sladek, University of California, Riverside, CA.

Transfections
Cells were transfected by the calcium phosphate precipitate method, essentially as described by Rosenthal (27). Briefly, cells were plated at a density of 1.5 x 105 cells/6 cm dish and incubated for 20 h at 37 C. Precipitated DNA (5 µg luciferase expression construct plus 2 µg CMV-ßgal construct) was added directly to the dishes. After 8 h, the cells were shocked by treating them with 5 ml 10% dimethylsulfoxide (DMSO) in serum-free MEM for 90 sec. The DMSO solution was then aspirated, and 3 ml fresh medium with 10% serum was added to each dish. Cells were allowed to recover for 40 h and were then treated with PGA2. Cells were harvested 24 h later by scraping them into 450 µl lysis buffer (50 mM Tris-HCl, pH 7.5, 1 mM dithiothreitol, and 1% Triton X-100). Luciferase assays were performed using LAR buffer as the assay buffer (20 mM Tricine, pH 7.8, 1.07 mM (MgCO3)4 Mg(OH)2·5H2O, 2.67 mM MgSO4, 0.1 mM EDTA, 33.3 mM dithiothreitol, 270 µM coenzyme A, 530 µM ATP, 470 µM luciferin) (28) in a Monolight 2010 luminometer (Analytical Luminescence Laboratory, San Diego, CA). ß-galactosidase activity was determined as described in Rosenthal (27), except that the reaction was stopped by addition of 0.5 ml 1 M glycine (pH 9.8), to yield a final concentration of 0.65 M glycine.

RNA preparation
Whole cellular RNA (cytoplasmic plus nuclear) was extracted from cultured C6 cells using a modification of the guanidine thiocyanate method, as described previously (29). RNA samples to be analyzed by RT-PCR were treated with RNase-free DNase (RQ1 DNase, Promega) at a concentration of 2.5 U/ml in DNase buffer (50 mM Tris-HCl, pH 7.8, 1 mM MgCl2, 1 mM CaCl2, 100 U/ml RNasin) for 20 min at 37 C. Samples were then extracted twice with phenol-chloroform, and reprecipitated with ethanol.

Northern blot analysis
For Northern blot analysis, RNA samples were denatured and electrophoresed in 1% agarose gels containing 2.2 M formaldehyde, and the RNA was transferred onto nylon filters. Even loading of the gels was confirmed by ethidium bromide staining. The DNA probes (gel-purified restriction fragments of cDNA clones) were labeled by random priming with [{alpha}32P]deoxycytidine triphosphate. Filters were prehybridized, hybridized, and washed as described previously (29, 30, 31). Results were quantified by scanning autoradiograms with an LKB UltroScan laser densitometer, exercising caution to stay within the linear range of the film (31).

PCR primers and PCR fragment subcloning
For amplification of IGF-I nuclear transcripts by RT-PCR, oligonucleotide primers were used that correspond to bases 13 through 32 (oligonucleotide IGF1) and bases 314 through 333 (oligonucleotide IGF2) of intron 5 of the rat IGF-I gene sequence (32). [Subsequent to the publication of Shimatsu and Rotwein (32), the exons of the rat IGF-I gene have been renumbered, so that exon 4 in Shimatsu and Rotwein (32) is now exon 5 (26). Also, the correct splice junction between exon 5 and intron 5 is between nucleotides 421 and 422 of the exon 4 sequence presented in Shimatsu and Rotwein (32) Fig. 3Go (33).] The sequences of the oligonucleotides were 5'-CACACCCAGGAGGGGAACAG-3' (IGF1) and 5'-GTGTTGTTGATGCTCCGTCC-3' (IGF2). Primers used for RT-PCR analysis of hypoxanthine-guanine phosphoribosyl transferase (HPRT) nuclear transcripts corresponded to the last 20 bases of exon 7 (oligonucleotide HPRT1) and the last 2 bases of intron 7 plus the first 21 bases of exon 8 (oligonucleotide HPRT2) of the rat HPRT gene (34, 35, 36, 37). The sequences of the oligonucleotides were 5'-GTTGGATACAGGCCAGACTG-3' (HPRT1) and 5'-CTGGAATTTCAAATCCAACAACT-3' (HPRT2).



View larger version (68K):
[in this window]
[in a new window]
  		Figure 3. Time course for effect of PGA2 on IGF-I mRNA (A), cyclin D1 mRNA (B), Waf1 mRNA (C), and 28S ribosomal RNA (D). PGA2 was added at T = 0, and cells were harvested at T = 0, 4, 8, 12, or 24 h. Cultures treated with PGA2: lanes 5, 6, 9, 10, 13, 14, 17, 18; control cultures: lanes 1, 2, 3, 4, 7, 8, 11, 12, 15, 16. Cells were harvested at indicated times, and RNA was extracted for Northern blot analysis.

 
Using the IGF-I primers, a single product with a molecular size of 321 bp was generated by PCR amplification of either rat genomic DNA (spleen DNA prepared from a single Sprague-Dawley rat) or PCR amplification of a 4.2-kb rat IGF-I genomic clone (30) covering exons 4 and 5 and the beginning of intron 5. The 321-bp product obtained by amplification of the 4.2-kb genomic clone was subcloned into the TA cloning vector (Invitrogen, San Diego, CA). A single product with a molecular size of approximately 210 bp was obtained by PCR amplification of rat genomic DNA using the HPRT primers. This fragment was also subcloned into the TA cloning vector.

Reverse transcription-PCR
Before reverse transcription, 0.5 µg total RNA and 3 µg random hexamer primers (GIBCO BRL, Gaithersburg, MD) were preheated to 70 C. After 10 min, the mixture was quick-cooled in a dry ice/ethanol bath. Reverse transcription with 200 U SuperscriptII RNaseH- reverse transcriptase was performed in first-strand buffer (GIBCO BRL), 1 mM deoxynucleotide triphosphates, 10 mM dithiothreitol, 0.4 U/µl RNasin (Promega), and 0.1 µg/µl BSA, in a final volume of 20 µl, at 37 C for 1 h. The reaction product was then diluted to 50 µl with water.

PCR amplification was performed with Taq polymerase (Perkin Elmer, Norwalk, CT) with 2 µl of the diluted reverse transcription product. Amplification with the IGF-I primers was allowed to occur over 20 cycles consisting of 95 C (1.5 min), 60 C (1.5 min), and 72 C (3 min) followed by 15 min of final extension at 72 C. For analysis of HPRT transcript levels, the same reverse transcription product was also amplified in a different tube with the HPRT primers for 27 cycles using the same temperature and time parameters.

The PCR products were electrophoresed in 2% agarose gels and then blotted onto nylon filters. Gel-purified inserts from the DNA subclones corresponding to the amplified IGF-I and HPRT fragments were labeled by random priming and hybridized to the filters. Data were quantified by scanning autoradiograms with an LKB UltroScan laser densitometer or by image analysis with a Molecular Dynamics PhosphorImager. When results were quantified by autoradiography and scanning densitometry, caution was exercised to stay within the linear range of the x-ray film (31). The RT-PCR assay was linear with respect to template RNA (see Results below).

Statistical analysis
The significance of the difference between two means was determined by the unpaired Student’s t test, using P < 0.05 as the cutoff for significance. For comparison of more than two means, data were subjected to ANOVA followed by the Student-Newman-Keuls multiple comparison test, with a probability value {alpha} = 0.05 used to evaluate significance. Linear regression analysis was performed using the GraphPAD graphics program (GraphPAD Software, San Diego, CA). The significance of the difference between the slope of a line and zero was evaluated by the t test, using P < 0.05 as the cutoff for significance.


   Results
Top
 Abstract
 Introduction
 Materials and Methods
 Results
Discussion
 References
 
A Northern blot illustrating the effect of increasing concentrations of PGA2 on IGF-I mRNA abundance is shown in Fig. 1AGo. Quantitative analysis of the results (Fig. 2AGo) indicated that PGA2 repressed the expression of the IGF-I gene at concentrations >=10 µM. At 20 µM PGA2, the abundance of IGF-I mRNA was decreased by 14-fold. At this concentration, cell growth was inhibited, but there was no obvious sign of cytotoxicity of PGA2 (see below). The effect of PGA2 on IGF-I mRNA was specific, because PGA2 did not have any significant effect on the abundance of HPRT or ubiquitin mRNA (Figs. 1Go, B and C and 2, B and C).



View larger version (51K):
[in this window]
[in a new window]
  		Figure 1. Dose-response experiment showing effect of varying concentrations of PGA2 on IGF-I mRNA (A), HPRT mRNA (B), and ubiquitin mRNA (C). Cells were treated with PGA2 for 24 h. RNA was then extracted, and Northern blots were prepared using 20 µg RNA/gel lane. Lanes 1–2, Control treated with vehicle alone; lanes 3–4, 2.5 µM PGA2; lanes 5–6, 5 µM PGA2; lanes 7–8, 10 µM PGA2; lanes 9–10, 15 µM PGA2; lanes 11–12, 20 µM PGA2. The 1.3 kb ubiquitin mRNA species is product of UbB gene; 3.0 and 3.9 kb mRNA species are product of UbC gene (38).

 


View larger version (20K):
[in this window]
[in a new window]
  		Figure 2. Effect of increasing concentrations of PGA2 on abundance of IGF-I mRNA (A), HPRT mRNA (B), and ubiquitin mRNA (C). Data from autoradiograms shown in Fig. 1Go were quantified by scanning densitometry. A, Results for major 8 kb IGF-I mRNA species. C, Results for 1.3 kb UbB mRNA species. Each point represents mean of results obtained with RNA preparations from two different cultures with error bars indicating range for two determinations. Error bars for some points are not shown because they are smaller than the radius of the symbol for those points. All data were analyzed by linear regression analysis. Results presented in A show a significant downward trend with increasing PGA2 concentrations (r = -0.9715, P = 0.0012), whereas results presented in B and C do not show a significant upward or downward trend (r = -0.4550, P = 0.3646 for B and r = 0.1670, P = 0.7519 for C).

 
We next performed experiments to determine the time course for the effect of PGA2 on IGF-I mRNA (Fig. 3AGo). As we reported previously, the abundance of IGF-I mRNA in control, untreated cells increased over time with increasing cell density (38). PGA2 caused a rapid decrease in IGF-I mRNA abundance in treated as compared with control cells, which was evident at times as early as 4 h after addition of PGA2. Furthermore, PGA2 not only prevented the steady time-dependent increase in IGF-I mRNA that occurred in control cells, but it also decreased the abundance of IGF-I mRNA below the T = 0 baseline (Figs. 3AGo and 4AGo). PGA2 has been shown previously to increase the expression of the cdk inhibitor Waf1 in some cell lines and to decrease the expression of cyclin D1 (6, 11). To determine whether PGA2 regulated the expression of these two genes in the C6 cells, the abundance of cyclin D1 and Waf1 mRNA was determined in the time course experiment illustrated in Fig. 3Go. The results indicated that Waf1 mRNA abundance was increased within 4 h after PGA2 addition, whereas cyclin D1 mRNA was repressed by 8 h after PGA2 addition (Figs. 3Go, B and C and 4, B and C).



View larger version (20K):
[in this window]
[in a new window]
  		Figure 4. Results of densitometric scans of blots illustrated in Fig. 3Go. Results were quantified by densitometric scanning of major 8 kb IGF-I mRNA (A), cyclin D1 mRNA (B), and Waf1 mRNA (C). Control cultures {circ}; PGA2-treated cultures •. Each point is mean of results obtained with two different cultures, with error bar indicating range for two determinations. Error bars for some points are not shown because they are smaller than the radius of the symbol for these points.

 
The effect of PGA2 on growth of the C6 cells is shown in Fig. 5Go. PGA2 caused a significant inhibition of growth, which was evident within 12 h after PGA2 addition (Fig. 5AGo). Analysis of cellular DNA content by flow cytometry (FACScan) indicated that PGA2 increased the fraction of cells in the G1 phase of the cell cycle (Fig. 5BGo). PGA2 at a concentration of 20 µM did not have any obvious cytotoxic effect on the cells, nor did it increase the fraction of dead cells in the cultures as indicated by trypan blue staining: the fraction of cells stained with trypan blue was <1% in both control and treated cultures. To determine whether IGF-I might be capable of reversing the growth-inhibitory effect of PGA2, we performed experiments in which cells were treated with PGA2 or PGA2 plus IGF-I. The results (Fig. 5CGo) indicated that IGF-I was able to partially reverse the growth-inhibitory effect of PGA2.



View larger version (34K):
[in this window]
[in a new window]
  		Figure 5. Effect of PGA2 on growth and cell cycle distribution of C6 cells. A, Effect of PGA2 on cell number. PGA2 was added at T = 0, and cells were harvested at T = 12 or 24 h. Each bar represents mean cell count for three different dishes ± SE. *, Significantly lower than control at 12 h (P < 0.05) and 24 h (P < 0.005). B, FACScan analysis of control and PGA2-treated C6 cultures. Right, PGA2 was added to log phase culture at T = 0, and cells were harvested, fixed, and subjected to FACScan analysis 24 h later. Left, Control culture not treated with PGA2. Numbers in panels represent percentage of cells in different phases of cell cycle. C, Effect of exogenous IGF-I on growth of PGA2-treated cells. IGF-I (50 ng/ml, 7 nM) or vehicle (5 nM acetic acid) were added as indicated at T = 0 in presence or absence of PGA2 (20 µM). Cells were harvested and counted at T = 24 h. Data represent pooled results of two experiments, each performed in triplicate; therefore, each bar represents mean cell count from six different cultures ± SE. Data were subjected to ANOVA followed by Student-Newman-Keuls multiple comparison test using {alpha} = 0.05 as cutoff for significance. Means with different letters are significantly different.

 
To determine whether the regulation by PGA2 of IGF-I mRNA abundance in the C6 cells results from a change in IGF-I gene transcription, a sensitive assay for IGF-I nuclear transcripts was developed using RT-PCR. The primers for this assay are two 20-mers corresponding to sequences located in intron 5 of the rat IGF-I gene (Fig. 6Go). This assay measures the abundance of the IGF-I primary nuclear transcript and splicing intermediates still containing intron 5. A similar assay has been developed for quantifying HPRT nuclear transcripts, which are used as a control. This assay involves amplification of intron 7 of the HPRT gene and therefore detects the HPRT primary transcript and splicing intermediates still containing intron 7. All RNA samples used in the RT-PCR assays were treated with RNase-free DNase I before reverse transcription. Control assays in which the reverse transcription step was omitted consistently failed to yield amplified product, indicating that the DNase I treatment removed any genomic DNA that might have been present in the RNA preparations (results not shown).



View larger version (14K):
[in this window]
[in a new window]
  		Figure 6. Location of primers used for RT-PCR amplification of IGF-I nuclear transcripts (A) and HPRT nuclear transcripts (B).

 
Because of the well-known plateau effect in PCR amplification, it is important in quantitative applications of RT-PCR to work below the plateau range with respect to cycle number, so that the assay is linear with respect to RNA template. At 20 cycles of PCR amplification, the assay for IGF-I nuclear transcripts was linear with respect to RNA template in amounts ranging from 0.05–1.5 µg (Fig. 7Go, A and C). At 27 cycles of PCR amplification, the assay for HPRT nuclear transcripts also was linear with respect to RNA template in amounts ranging from 0.05–1.5 µg (Fig. 7Go, B and D).



View larger version (23K):
[in this window]
[in a new window]
  		Figure 7. Linearity of RT-PCR assay of IGF-I (A and C) and HPRT (B and D) nuclear transcripts. Whole cellular RNA was prepared from exponentially growing cells as described in Materials and Methods. Various amounts of total RNA were reverse-tran-scribed and subjected to 20 cycles of PCR using IGF-I primers or 27 cycles of PCR using HPRT primers. Amplified fragments were detected by Southern blot analysis (see Materials and Methods). In A and B, amounts of RNA used were 0.05 µg (lanes 1–2), 0.1 µg (lanes 3–4), 0.3 µg (lanes 5–6), 0.5 µg (lanes 7–8), 1.0 µg (lanes 9–10), and 1.5 µg (lanes 11–12). C and D, Results of phosphorimage analysis of blots shown in A and B. Each point is average of duplicate assays. Data in C and D were subjected to linear re-gression analysis, imposing the requirement that the line pass through the origin (C, r = 0.9954, P < 0.0001; D, r = 0.9980, P < 0.0001).

 
To determine whether PGA2 decreased the level of IGF-I nuclear transcripts, RNA was prepared from control and PGA2-treated cells and analyzed for IGF-I and HPRT nuclear transcripts. The results (Fig. 8Go, A and B) indicated that treatment with PGA2 resulted in a 6.2-fold decrease in IGF-I mRNA and a 6.4-fold decrease in IGF-I nuclear transcripts. These results indicate that the repression by PGA2 of IGF-I gene expression is caused largely by a decrease in IGF-I nuclear transcript levels. HPRT mRNA and nuclear transcripts were not significantly affected by PGA2, indicating that the effect of PGA2 on IGF-I nuclear transcript and mRNA abundance was gene-specific (Fig. 8Go, C and D).



View larger version (47K):
[in this window]
[in a new window]
  		Figure 8. Effect of PGA2 on IGF-I and HPRT mRNA and nuclear transcripts. Six dishes were treated with PGA2 for 24 h, and six dishes were treated with vehicle (control). Whole cellular RNA was prepared from each culture and subjected to Northern blot analysis for detection of IGF-I mRNA (major 8 kb species, A) and HPRT mRNA (C), and RT-PCR for detection of nuclear transcripts (B and D). Results were analyzed by densitometric scanning of autoradiograms. Each bar represents mean of results obtained with RNA preparations from six different cultures ± SE. *, Significantly different from control, P < 0.05.

 
In an attempt to identify the cis-acting element that mediates the effect of PGA2 on IGF-I gene transcription, C6 cells were transiently transfected with IGF-I/luciferase expression constructs in which luciferase expression was driven by P1 promoter fragments extending from -1711 to +328 or from -1114 to +328 relative to the beginning of exon 1. Transient transfections were also performed with the pGL3 promoterless luciferase vector, which served as a control. A CMV-ßgal expression construct was cotransfected along with each construct to control for variability in transfection efficiency. The results (Fig. 9Go) indicated that treatment with PGA2 did not repress luciferase expression in cells transfected with the IGF/luciferase constructs, and in fact, increased luciferase expression by about 2-fold. The increase in luciferase expression was nonspecific, because it was also observed with the pGL3 promoterless vector. In the experiment illustrated in Fig. 9Go, luciferase data were normalized to ß-galactosidase activity to correct for differences in transfection efficiency. The activity of ß-galactosidase was slightly increased in the cultures treated with PGA2, so that the increase in normalized luciferase activity was not caused by a decrease in ß-galactosidase activity. An alternative method for normalizing luciferase data is to normalize to total cellular protein (39, 40). The results illustrated in Fig. 9Go were very similar if the data were normalized to cellular protein: again, PGA2 treatment increased rather than decreased normalized luciferase activity (data not shown). Based on the results of the transient transfection experiments, we conclude that a negative PGA2 regulatory element is not located in the -1711 to +328 interval of the IGF-I promoter.



View larger version (32K):
[in this window]
[in a new window]
  		Figure 9. Effect of PGA2 on luciferase expression in cells transiently transfected with IGF-I/luciferase expression constructs. C6 cells were transiently transfected as described in Materials and Methods. Cells were treated for 24 h with vehicle (open bars) or 20 µM PGA2 (cross-hatched bars), harvested, and assayed for luciferase and ß-galactosidase activity. Luciferase/ß-galactosidase ratio is shown for pGL3-Basic (no promoter), pGL3 containing -1114/+328 region of IGF-I P1 promoter, or pGL3 containing -1711/+328 region of IGF-I P1 promoter. *, Significantly different from control, P < 0.05.

 

   Discussion
Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
References
 
We present here the novel finding that PGA2 specifically represses IGF-I gene expression in C6 glioma cells. Thus, the IGF-I gene belongs to the family of genes that are repressed by cyclopentenone PGs: this family has been shown previously to include the genes encoding c-myc (12), N-myc (13), cyclin D1 (6), and cdk4 (6). At a concentration of 20 µM, PGA2 slowed the growth of the C6 cells and caused an increase in the fraction of cells in the G1 phase of the cell cycle, without any overt cytotoxic effect on the cells. This pattern of arrest in G1 without overt cytotoxicity is similar to that observed previously with PGA2-treated MCF-7 breast cancer cells (6) and human T-cell leukemia virus type I-immortalized MT-2 cells treated with PGA1 or PGJ2 (5).

IGF-I, acting via the IGF-I receptor, has been shown to protect a number of cell types from apoptosis (17, 18, 41, 42, 43). In addition, it is known that IGF-I serves as an autocrine factor for the C6 glioma cells in vivo, and that disruption of this autocrine loop results in suppression of tumorigenicity characterized by apoptosis of the tumor cell population (15, 16, 17, 18). The cyclopentenone PGs inhibit tumor cell growth in vivo and have been proposed as possible chemotherapeutic agents (1, 2, 3, 4). Inhibition of growth factor production by tumor cells could be a biologically significant action of the cyclopentenone PGs in suppression of tumorigenesis. PGA2 inhibits the growth of a variety of tumor cell types, only some of which express IGF-I. Therefore, inhibition of IGF-I production by tumor cells could be causally associated with growth arrest of only a subset of tumor cell types. The possibility that PGA2 might suppress the expression of autocrine factors other than IGF-I, or the production of growth factors by normal stromal cells, which can act in a paracrine fashion on tumor cells, remains to be explored.

In the present study, we used a simple quantitative RT-PCR assay for IGF-I nuclear transcripts. This method involves amplifying nuclear pre-mRNA sequences by RT-PCR, with primers located within or flanking an intron. The only RNA sequences that can act as templates for this amplification are the primary nuclear transcript and splicing intermediates that still contain the intron. As in previous studies in which we quantified nuclear transcripts by Northern blot analysis or RNase protection assay (29, 44, 45, 46), in the present study nuclear transcripts were used to estimate transcriptional activity. The RT-PCR assay offers the advantage of extreme sensitivity for detection of nuclear transcripts and can therefore be used in situations in which transcript levels are too low to be detected by other methods. RT-PCR has been used previously by others for quantitative measurement of nuclear transcript levels, and in experiments in which both transcription run-on assays and RT-PCR assays were performed, the results of the two assays agreed quite well (47, 48, 49, 50, 51). Thus in most experimental situations, measurements of nuclear transcript levels appear to provide a valid estimate of transcriptional activity (29, 44, 45, 46, 47, 48, 49, 50, 51).

The decrease in abundance of IGF-I mRNA in response to PGA2 was accompanied by a nearly identical decrease in the abundance of IGF-I nuclear transcripts. These changes were specific, as HPRT mRNA and nuclear transcripts were not decreased in PGA2-treated cells. These results suggest that the decreased expression of the IGF-I gene in response to PGA2 results from a specific repression of IGF-I gene transcription. Because the steady-state level of IGF-I nuclear transcripts is determined by both rate of synthesis and rate of splicing, we cannot formally rule out the possibility that IGF-I nuclear transcripts were regulated by a specific change in the rate of splicing of IGF-I nuclear transcripts. This seems unlikely, however, because a decrease in the rate of splicing would be expected to cause a decrease in IGF-I mRNA but an increase in IGF-I nuclear transcripts (52), which is not what we observed. Conversely, an increase in the rate of splicing would not be expected to caused a decrease in IGF-I mRNA.

The molecular basis for IGF-I gene repression by PGA2 remains an interesting question. The related cyclopentenone prostaglandin PGJ2 is an isomer of PGA2. Recently, a metabolite of PGJ2, 15-deoxy-{Delta}12,14-PGJ2 (15d-PGJ2), has been shown to activate the transcription of genes involved in adipogenesis by binding to the {gamma}-isoform of the peroxisome proliferator-activated receptor (PPAR{gamma}) (53, 54). However, other ligands of the PPAR{gamma} receptor that are active in inducing adipogenesis do not inhibit cell proliferation, leading to speculation that the growth-inhibitory activity of 15d-PGJ2 may be mediated by another PPAR receptor isoform such as PPAR{delta} (53). PGA1 and PGA2 are also strongly growth inhibitory, and the potential interaction of these two PGs with the various PPAR receptor isoforms has not yet been characterized fully. However, it has been demonstrated recently that in transient transfection assays PGA1 and PGA2 are both capable of activating the PPAR{delta} receptor, with PGA1 being the more potent activator (55). Unlike the PPAR{alpha} and {gamma} receptors, which have limited tissue distribution, the PPAR{delta} receptor is ubiquitously expressed (56) and is therefore very likely present in the C6 glioma cells. Although activation of PPAR receptors would normally be associated with the activation of gene transcription, a number of other nuclear receptors are known to either activate or repress gene transcription, depending on the context (57, 58, 59). Alternatively, PGA2 activates a cascade of cellular events culminating in decreased phosphorylation of Rb, which is predicted to have a repressive effect on genes such as c-myc that utilize E2F for activation of transcription (6, 60). Based on the results of the transient transfection assays, the cis-acting element that mediates the repressive effect of PGA2 on IGF-I gene transcription appears to be located outside the -1711 to +328 P1 promoter interval. The location of this element remains to be determined, as does the molecular mechanism for negative regulation of gene expression by PGA2.

Previous studies have demonstrated that PGA2 represses cyclin D1 gene expression in MCF-7 breast cancer cells, and increases the expression of Waf1 in some but not all cell types (6, 11). Both of these two effects of PGA2 were observed in the C6 glioma cells. Cyclin D1 stimulates and Waf1 inhibits the G1 cyclin-dependent protein kinase cdk4 (61). Thus, the concerted induction of Waf1 and repression of cyclin D1 could be causally associated with growth arrest in the G1 phase of the cell cycle. Because IGF-I partially reversed the growth-inhibitory effect of PGA2, IGF-I is at least partially dominant over PGA2 at the doses used in this study. This result is consistent with a cause-effect relationship between the repression by PGA2 of IGF-I gene expression and cell cycle arrest, although it is also consistent with a model in which PGA2 and IGF-I regulate the same endpoint (i.e. progression through the G1 phase of the cell cycle) independently and in opposite directions. It has been shown previously that IGF-I increases cyclin D1 expression (62). The decrease in cyclin D1 mRNA occurred after the decrease in IGF-I mRNA; thus, it is conceivable that decreased IGF-I expression contributed to the decrease in cyclin D1 mRNA in the C6 cells. In contrast, the induction of Waf1 mRNA occurred at least as early as the repression of IGF-I mRNA. Therefore, it is very unlikely that the decreased expression of IGF-I is causally associated with Waf1 induction. Further knowledge of the molecular pathway(s) by which PGA2 regulates gene expression should help clarify which of the effects of PGA2 on gene expression are related to each other in a cause-effect manner and which occur independently.


   Acknowledgments
 
We thank G. Robertson for generous assistance with the FACScan analysis.


   Footnotes
 
1 This research was supported by NIH Grants DK-39739 (to D.S.S.) and DK-37449 (to P.R.). Back

2 Present address: Division of Molecular Medicine, Department of Medicine, Oregon Health Sciences University, 3181 Southwest Sam Jackson Park Road, Portland, Oregon 97201. Back

Received August 1, 1996.


   References
Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 References
 

  1. Fukushima M 1990 Prostaglandin J2-antitumour and anti-viral activities and mechanisms involved. Ecosanoids 3:189–199
  2. Fukushima M 1992 Biological activities and mechanisms of action of PGJ2 and related compounds: an update. Prostaglandins Leukot Essent Fatty Acids 47:1–12[CrossRef][Medline]
  3. Sasaki H, Fukushima M 1994 Prostaglandins in the treatment of cancer. Anti-Cancer Drugs 5:131–138[Medline]
  4. Fukushima M, Sasaki H, Fukushima S 1994 Prostaglandin J2 and related compounds. Mode of action in G1 arrest and preclinical results. Ann NY Acad Sci 744:161–165[Medline]
  5. D’Onofrio C, Amici C, Puglianiello A, Faraoni I, Lanzilli G, Santoro MG, Bonmassar E 1992 Comparative anti-viral and anti-proliferative activity of PGA1 and PGJ2 against HTLV-I-infected MT-2 cells. Int J Cancer 51:481–488[Medline]
  6. Gorospe M, Liu Y, Xu Q, Chrest FJ, Holbrook NJ 1996 Inhibition of G1 cyclin-dependent kinase activity during growth arrest of human breast carcinoma cells by prostaglandin A2. Mol Cell Biol 16:762–770[Abstract]
  7. Holbrook NJ, Carlson SG, Choi AMK, Fargnoli J 1992 Induction of HSP70 gene expression by the antiproliferative prostaglandin PGA2: a growth-dependent response mediated by activation of heat shock transcription factor. Mol Cell Biol 12:1528–1534[Abstract/Free Full Text]
  8. Amici C, Sistonen L, Santoro MG, Morimoto RI 1992 Antiproliferative prostaglandins activate heat shock transcription factor. Proc Natl Acad Sci USA 89:6227–6231[Abstract/Free Full Text]
  9. Choi AMK, Tucker RW, Carlson SG, Wiegand G, Holbrook NJ 1994 Calcium mediates expression of stress-response genes in prostaglandin A2-induced growth arrest. FASEB J 8:1048–1054[Abstract]
  10. Choi AMK, Fargnoli J, Carlson SG, Holbrook NJ 1992 Cell growth inhibition by prostaglandin A2 results in elevated expression of gadd153 mRNA. Exp Cell Res 199:85–89[CrossRef][Medline]
  11. Gorospe M, Holbrook NJ 1996 Role of p21 in prostaglandin A2-mediated cellular arrest and death. Cancer Res 56:475–479[Abstract/Free Full Text]
  12. Ishioka C, Kanamaru R, Sato T, Dei T, Konishi Y, Asamura M, Wakui A 1988 Inhibitory effects of prostaglandin A2 on c-myc expression and cell cycle progression in human leukemia cell line HL-60. Cancer Res 48:2813–2818[Abstract/Free Full Text]
  13. Marui N, Sakai T, Hosokawa N, Yoshida M, Aoike A, Kawai K, Nishino H, Fukushima M 1990 N-myc suppression and cell cycle arrest at G1 phase by prostaglandins. FEBS Lett 270:15–18[CrossRef][Medline]
  14. Lowe, Jr, WL, Meyer T, Karpen CW, Lorentzen LR 1992 Regulation of insulin-like growth factor I production in rat C6 glioma cells: possible role as an autocrine/paracrine growth factor. Endocrinology 130:2683–2691[Abstract/Free Full Text]
  15. Trojan J, Blossey BK, Johnson TR, Rudin SD, Tykocinski M, Ilan J, Ilan J 1992 Loss of tumorigenicity of rat glioblastoma directed by episome-based antisense cDNA transcription of insulin-like growth factor I. Proc Natl Acad Sci USA 89:4874–4878[Abstract/Free Full Text]
  16. Resnicoff M, Sell C, Rubini M, Coppola D, Ambrose D, Baserga R, Rubin R 1994 Rat glioblastoma cells expressing an antisense RNA to the insulin-like growth factor-I (IGF-I) receptor are nontumorigenic and induce regression of wild-type tumors. Cancer Res 54:2218–2222[Abstract/Free Full Text]
  17. Resnicoff M, Abraham D, Yutanawiboonchai W, Rotman HL Kajstura J, Rubin R, Zoltick P, Baserga R 1995 The insulin-like growth factor I receptor protects tumor cells from apoptosis in vivo. Cancer Res 55:2463–2469[Abstract/Free Full Text]
  18. Resnicoff M, Burgaud JL, Rotman HL, Abraham D, Baserga R 1995 Correlation between apoptosis, tumorigenesis, and levels of insulin-like growth factor I receptors. Cancer Res 55:3739–3741[Abstract/Free Full Text]
  19. Becton Dickinson Monoclonal Antibodies Source Book 1989 Becton Dickinson Immunocytochemistry Systems, San Jose CA, Section 1.11
  20. Braylan RC, Benson NA, Nourse V, Kruth HS 1982 Correlated analysis of cellular DNA, membrane antigens and light scatter of human lymphoid cells. Cytometry 2:337–343[Medline]
  21. Murphy LJ, Bell GI, Duckworth ML, Friesen HG 1987 Identification, characterization, and regulation of a rat complementary deoxyribonucleic acid which encodes insulin-like growth factor-I. Endocrinology 121:684–691[Abstract/Free Full Text]
  22. Fornace, Jr, AJ, Alamo, Jr, I, Hollander MC, Lamoreaux E 1989 Ubiquitin mRNA is a major stress-induced transcript in mammalian cells. Nucleic Acids Res 17:1215–1230[Abstract/Free Full Text]
  23. Smith R, Peters G, Dickson C 1995 Genomic organization of the mouse cyclin D1 gene (cyl-1). Genomics 25:85–92[CrossRef][Medline]
  24. Huppi K, Siwarski D, Dosik J, Michieli P, Chedid M, Reed S, Mock B, Givol D, Mushinski JF 1994 Molecular cloning, sequencing, chromosomal localization and expression of mouse p21 (Waf1). Oncogene 9:3017–3020[Medline]
  25. Chikaraishi DM, Buchanan L, Danna KJ, Harrington CA 1983 Genomic organization of rat rDNA. Nucleic Acids Res 11:6437–6452[Abstract/Free Full Text]
  26. Hall LJ, Kajimoto Y, Bichell D, Kim SW, James PL, Counts D, Nixon LJ, Tobin G, Rotwein P 1992 Functional analysis of the rat insulin-like growth factor I gene and identification of an IGF-I gene promoter. DNA Cell Biol 11:301–313[Medline]
  27. Rosenthal N 1987 Identification of regulatory elements of cloned genes and functional assays. Methods Enzymol 152:704–720[Medline]
  28. Luehrsen KR, de Wet JR, Walbot V 1992 Transient expression analysis in plants using firefly luciferase reporter gene. Methods Enzymol 216:397–414[Medline]
  29. Straus DS, Burke EJ, Marten NW 1993 Induction of insulin-like growth factor binding protein-1 gene expression in liver of protein-restricted rats and in rat hepatoma cells limited for a single amino acid. Endocrinology 132:1090–1100[Abstract/Free Full Text]
  30. Straus DS, Takemoto CD 1990 Effect of fasting on insulin-like growth factor-I (IGF-I) and growth hormone receptor mRNA levels and IGF-I gene transcription in rat liver. Mol Endocrinol 4:91–100[Abstract/Free Full Text]
  31. Straus DS, Takemoto CD 1990 Effect of dietary protein deprivation on insulin-like growth factor (IGF)-I and -II, IGF binding protein-2, and serum albumin gene expression in rat. Endocrinology 127:1849–1860[Abstract/Free Full Text]
  32. Shimatsu A, Rotwein P 1987 Mosaic evolution of the insulin-like growth factors. Organization, sequence and expression of the rat insulin-like growth factor I gene. J Biol Chem 262:7894–7900[Abstract/Free Full Text]
  33. Daughaday WH, Rotwein P 1989 Insulin-like growth factors I and II. Peptide, messenger ribonucleic acid and gene structures, serum and tissue concentrations. Endocr Rev 10:68–91[Abstract/Free Full Text]
  34. Jansen JG, Vrieling H, von Zeeland AA, Mohn GR 1992 The gene encoding hypoxanthine-guanine phosphoribosyltransferase as target for mutational analysis: PCR cloning and sequencing of the cDNA from the rat. Mutat Res 266:105–116[CrossRef][Medline]
  35. Melton DW, Konecki DS, Brennand J, Caskey CT 1984 Structure, expression, and mutation of the hypoxanthine phosphoribosyltransferase gene. Proc Natl Acad Sci USA 81:2147–2151[Abstract/Free Full Text]
  36. Edwards A, Voss H, Rice P, Civitello A, Stegemann J, Schwager C, Zimmermann J, Erfle H, Caskey CT, Ansorge W 1990 Automated DNA sequencing of the human HPRT locus. Genomics 6:593–608[CrossRef][Medline]
  37. Rossiter BJ, Fuscoe JC, Muzny DM, Fox M, Caskey CT 1991 The Chinese hamster HPRT gene: restriction map, sequence analysis, and multiplex PCR deletion screen. Genomics 9:247–256[CrossRef][Medline]
  38. Straus DS, Burke EJ 1995 Glucose stimulates IGF-I gene expression in C6 glioma cells. Endocrinology 136:365–368[Abstract]
  39. An MR, Lowe, Jr, WL 1995 The major promoter of the rat insulin-like growth factor-I gene binds a protein complex that is required for basal expression. Mol Cell Endocrinol 114:77–89[CrossRef][Medline]
  40. Odagiri H, Wang J, German MS 1996 Function of the human insulin promoter in primary cultured islet cells. J Biol Chem 271:1909–1915[Abstract/Free Full Text]
  41. Rubin R, Baserga R 1995 Insulin-like growth factor-I receptor. Its role in cell proliferation, apoptosis, and tumorigenicity. Lab Invest 73:311–331[Medline]
  42. Matthews CC, Feldman EL 1996 Insulin-like growth factor I rescues SH-SY5Y human neuroblastoma cells from hyperosmotic induced programmed cell death. J Cell Physiol 166:323–331[CrossRef][Medline]
  43. Stewart CEH, Rotwein P An insulin-like growth factor-stimulated phosphotidylinositol 3-kinase (PI3K) pathway mediates myoblast survival. Program of the 10th International Congress of Endocrinology, San Francisco CA, 1996 (Abstract OR34–2)
  44. Hayden JM, Marten NW, Burke EJ, Straus DS 1994 The effect of fasting on insulin-like growth factor-I nuclear transcript abundance in rat liver. Endocrinology 134:760–768[Abstract/Free Full Text]
  45. Hayden JM, Straus DS 1995 Insulin-like growth factor-I and serine protease inhibitor 2.1 nuclear transcript abundance in rat liver during protein restriction. J Endocrinol 145:397–407[Abstract/Free Full Text]
  46. Straus DS, Marten NW, Hayden JM, Burke EJ 1994 Protein restriction specifically decreases the abundance of serum albumin and transthyretin nuclear transcripts in rat liver. J Nutr 124:1041–1051
  47. Lipson KE, Baserga R 1989 Transcriptional activity of the human thymidine kinase gene determined by a method using PCR and an intron-specific probe. Proc Natl Acad Sci USA 86:9774–9777[Abstract/Free Full Text]
  48. Chang CD, Ottavio L, Travali S, Lipson KE, Baserga R 1990 Transcriptional and posttranscriptional regulation of the proliferating cell nuclear antigen gene. Mol Cell Biol 10:3289–3296[Abstract/Free Full Text]
  49. Chang CD, Phillips P, Lipson KE, Cristofalo VJ, Baserga R 1991 Senescent human fibroblasts have a post-transcriptional block in the expression of the proliferating cell nuclear antigen gene. J Biol Chem 266:8663–8666[Abstract/Free Full Text]
  50. Owczarek CM, Enriquez-Harris P, Proudfoot NJ 1992 The primary transcription unit of the human {alpha}2 globin gene defined by quantitative RT/PCR. Nucleic Acids Res 20:851–858[Abstract/Free Full Text]
  51. Delany AM, Canalis E 1995 Transcriptional repression of insulin-like growth factor I by glucocorticoids in rat bone cells. Endocrinology 136:4776–4781[Abstract]
  52. Hardy WR, Sandri-Goldin RM 1994 Herpes simplex virus inhibits host cell splicing, and regulatory protein ICP27 is required for this effect. J Virol 68:7790–7799[Abstract/Free Full Text]
  53. Forman BM, Tontonoz P, Chen J, Brun RP, Spiegelman BM, Evans RM 1995 15-deoxy-{Delta}12,14-prostaglandin J2 is a ligand for the adipocyte determination factor PPAR{gamma}. Cell 83:803–812[CrossRef][Medline]
  54. Kliewer SA, Lenhard JM, Willson TM, Patel I, Morris DC, Lehmann JM 1995 A prostaglandin J2 metabolite binds peroxisome proliferator-activated receptor {gamma} and promotes adipocyte differentiation. Cell 83:813–819[CrossRef][Medline]
  55. Yu K, Bayona W, Kallen CB, Harding HP, Ravera CP, McMahon G, Brown M, Lazar MA 1995 Differential activation of peroxisome proliferator-activated receptors by eicosanoids. J Biol Chem 270:23975–23983[Abstract/Free Full Text]
  56. Kliewer SA, Forman BM, Blumberg B, Ong ES, Borgmeyer U, Mangelsdorf DJ, Umesono K, Evans RM 1994 Differential expression and activation of a family of murine peroxisome proliferator-activated receptors. Proc Natl Acad Sci USA 91:7355–7359[Abstract/Free Full Text]
  57. Pfahl M 1993 Nuclear receptor/AP-1 interaction. Endocr Rev 14:651–658[Abstract/Free Full Text]
  58. Caldenhove E, Liden J, Wissink S, Van de Stolpe A, Raaijmakers J, Koenderman L, Okret S, Gustafsson JA, Van der Saag PT 1995 Negative cross-talk between RelA and the glucocorticoid receptor: a possible mechanism for the antiinflammatory action of glucocorticoids. Mol Endocrinol 9:401–412[Abstract/Free Full Text]
  59. Kamei Y, Xu L, Heinzel T, Torchia J, Kurokawa R, Gloss B, Lin SC, Heyman RA, Rose DW, Glass CK, Rosenfeld MG 1996 A CBP integrator complex mediates transcriptional activation and AP-1 inhibition by nuclear receptors. Cell 85:403–414[CrossRef][Medline]
  60. Wong KK, Zou X, Merrell KT, Patel AJ, Marcu KB, Chellappan S, Calame K 1995 v-Abl activates c-myc transcription through the E2F site. Mol Cell Biol 15:6535–6544[Abstract]
  61. Weinberg RA 1995 The retinoblastoma protein and cell cycle control. Cell 81:323–330[CrossRef][Medline]
  62. Furlanetto RW, Harwell SE, Frick KK 1994 Insulin-like growth factor-I induces cyclin D1 expression in MG63 human osteosarcoma cells in vitro. Mol Endocrinol 4:510–517[Abstract/Free Full Text]



This article has been cited by other articles:


Home page
 Am. J. Physiol. Endocrinol. Metab.Home page
M. Granado, A. I Martin, M{a} A. Villanua, and A. Lopez-Calderon
Experimental arthritis inhibits the insulin-like growth factor-I axis and induces muscle wasting through cyclooxygenase-2 activation
Am J Physiol Endocrinol Metab, June 1, 2007; 292(6): E1656 - E1665.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Cell Physiol.Home page
G. E. McCall, D. L. Allen, F. Haddad, and K. M. Baldwin
Transcriptional regulation of IGF-I expression in skeletal muscle
Am J Physiol Cell Physiol, October 1, 2003; 285(4): C831 - C839.
[Abstract] [Full Text] [PDF]

Home page
 Cell Growth Differ.Home page
P. A. Campo, S. Das, C.-H. Hsiang, T. Bui, C. E. Samuel, and D. S. Straus
Translational Regulation of Cyclin D1 by 15-Deoxy-{Delta}12,14-Prostaglandin J2
Cell Growth Differ., September 1, 2002; 13(9): 409 - 420.
[Abstract] [Full Text] [PDF]

Home page
 EndocrinologyHome page
L. Wang and M. L. Adamo
Cyclic Adenosine 3',5'-Monophosphate Inhibits Insulin-Like Growth Factor I Gene Expression in Rat Glioma Cell Lines: Evidence for Regulation of Transcription and Messenger Ribonucleic Acid Stability
Endocrinology, July 1, 2001; 142(7): 3041 - 3050.
[Abstract] [Full Text] [PDF]

Home page
 Neuro Oncol DukeHome page
H. Hirano, M. B. S. Lopes, E. R. Laws Jr., T. Asakura, M. Goto, J. E. Carpenter, L. R. Karns, and S. R. VandenBerg
Insulin-like growth factor-1 content and pattern of expression correlates with histopathologic grade in diffusely infiltrating astrocytomas
Neuro-oncol, April 1, 1999; 1(2): 109 - 119.
[Abstract] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Bui, T.
Right arrow Articles by Straus, D. S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Bui, T.
Right arrow Articles by Straus, D. S.

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals